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Summary
Introduction Given the new therapeutic options in acromeg-
aly, it seemed important to evaluate the outcome of operated
acromegalic patients today.
Objective To analyse the characteristics and short- and long-
term surgical outcome of patients who underwent transsphenoi-
dal surgery for a growth hormone (GH)-secreting adenoma in
our centre and to determine predictive factors of remission.
Design and patients This retrospective 10-year study included
115 newly diagnosed acromegalic patients operated on at
Timone University Hospital, Marseille, France, between 1997
and 2007.
Measurements Initial and long-term outcomes were evaluated
using stringent and current remission criteria, associating GH
nadir after oral glucose tolerance test <04 lg/l and normal insu-
lin-like growth factor-1 (IGF-1) at 3 months, and a normal IGF-
1 at the end of follow-up (524 ± 368 months, median
41 months, range 67–1354 months, n = 99).
Results At the end of follow-up, 909% of patients had con-
trolled disease. Overall, 495% of patients were in long-term
remission after surgery alone, and only 20% of patients experi-
enced recurrent disease. Multivariate predictors of 3-month
remission included mean GH at diagnosis (P = 0033), tumour
invasion (P = 0013) and surgeon report of incomplete or
uncertain macroscopic resection (P = 0003 and P = 0047,
respectively). Multivariate predictors at diagnosis of long-term
remission included mean GH level (P = 0048), adenoma size
(P = 0007) and absence of pituitary deficit (P = 0026).
Conclusions In long-term follow-up after surgery of acromeg-
aly, half of the patients achieved remission after surgery alone
and more than 90% had their disease controlled. With stringent
3-month remission criteria, recurrence was rare.
(Received 24 April 2012; returned for revision 15 May 2012; finally
revised 28 June 2012; accepted 4 July 2012)
Introduction
Acromegaly is a rare chronic endocrine disease associated with
excessive production of growth hormone (GH).1 In most cases,
the condition is related to a pituitary adenoma, which develops
from somatotroph cells.2 Acromegaly is characterized by a dys-
morphic syndrome with disproportionate growth of skeletal tis-
sues and organs, accompanied by metabolic disturbances.3,4
Large retrospective studies showed patients with acromegaly had
on average a 10-year lower life expectancy than the general pop-
ulation, mainly due to cardiovascular disease.5,6
Treatment for acromegaly is aimed at reducing the tumour
volume, normalizing GH and insulin-like growth factor (IGF-1)
and improving symptoms and long-term morbidity and mortal-
ity.7–9 For this, transsphenoidal microsurgery is widely accepted
as the first-line therapy.4,10
Data show that acromegalic patients with IGF-1 levels above
normal and final GH levels above 25 lg/l continue to have sig-
nificantly higher mortality rates than the general population.5 As
the levels of these variables are lowered, the mortality rate begins
to improve. However, only patients with normal IGF-1 levels
and GH levels around 1 lg/l will have a mortality rate similar to
the normal population.5 Although GH and IGF-1 levels are usu-
ally closely correlated, discrepancies can occur. In most cases,
the reason for discrepancy is not clear and a close follow-up of
both parameters is necessary.11
Given the recent progress in the management of acromegaly
(including emerging knowledge and increased sensitivity of GH
assays), experts have proposed new evidence-based consensus
guidelines. Acromegaly is now considered ‘controlled’ in case of
age- and sex-normalized levels of IGF-1, associated with a random
GH level <1 lg/l or nadir GH after an oral glucose tolerance test
(OGTT) <04 lg/l.8 Note that previous studies had different
remission criteria, which makes efficacy comparison difficult.7
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In this 10-year retrospective study, we first analysed the char-
acteristics of patients who had surgery for a GH-secreting ade-
noma. We then evaluated their initial and long-term surgical
outcome using updated criteria for remission.8 We also tried to
identify factors linked to surgical remission, with the overall aim
of individualizing treatment and follow-up.
Patients and methods
Design and patients
A total of 155 patients with acromegaly were operated on
between 1997 and 2007 by two neurosurgeons at the Timone
University Hospital. Of these patients, 40 were excluded from
the current analysis for incomplete data (25 not followed in our
centre and 15 with <3 months postsurgery follow-up). We thus
collected and analysed retrospectively pre-, per- and post-opera-
tive data for 115 patients during their regular follow-up
(3 months after surgery and then yearly) including clinical, bio-
logical, radiological, surgical and anatomopathological (including
immunohistochemistry) results, and details concerning compli-
cations and treatment. Written informed consent was obtained
from all patients.
The diagnosis of acromegaly was made on the association of
clinical symptoms, elevated IGF-1 levels for patient’s age and
gender associated with failure of GH suppression during an
OGTT (GH  1 lg/l).7–9
Hormonal, ophthalmological and imaging evaluation
During the OGTT, GH levels were determined at 0, 30, 60, 90
and 120 min after ingestion of 75 g of glucose, and GH nadir
was used for analysis. Mean GH level (GHm) was calculated by
averaging nine hourly measurements (from 0800 to 1600 h).
Serum GH levels were determined by radioimmunoassay
{Immunotech, Marseille, France [1997–2002; Cisbio, Marseille,
France [2003 onwards)]}. Intra- and inter-assay coefficients of
variation were 066–15% and 131–14%, respectively, and sensi-
tivity was 005 lg/l. Levels of GH were expressed in lg/l or in
mIU/l (1 lg/l = 3 mIU/l).12
IGF-1 was ‘normalized’ using the upper limit of normal
(ULN), which was set as the age- and gender-adjusted 95th per-
centile in our laboratory. Plasma IGF-1 was measured by radio-
immunoassay (Immunotech) and standardized according to
normal values for age, gender and, if needed, pubertal status.
Intra- and inter-assay coefficients of variation were 26–74%
and 78–155%, respectively, and sensitivity was 3 ng/ml.
Thyroid-stimulating hormone (TSH) deficiency was defined as
a low free T4 level (free T4 <12 pM) with low or inappropriately
normal TSH level. Adrenocorticotropic hormone (ACTH) defi-
ciency was diagnosed if there was a low cortisol level (<200 nM)
with low or inappropriately normal ACTH level at 0800 h; an
insulin tolerance test was performed if cortisol was in the low-
to-normal range or in the presence of clinical symptoms. The
response was considered adequate if the cortisol peak was above
550 nM (with blood glucose nadir <22 mM). Gonadotrophin
deficiency was defined by low plasma sex steroids with inappro-
priate gonadotrophin levels (normal or low) and amenorrhoea
in nonmenopausal women, or a lack of increase in gonadotro-
phins in menopausal women. Hyperprolactinaemia was defined
as a basal plasma prolactin level >25 ng/ml. Posterior pituitary
function was assessed by clinical features, urinary volume, and
plasma and urinary osmolality.
Ophthalmologic evaluations using Goldman’s campimetry
were conducted in our ophthalmological centre.
Pituitary MRI was performed using sagittal and coronal sec-
tions and interpreted by neuroradiologists (Neuroradiology
Department, Timone Hospital). The sequences were spin echo
T1- and T2-weighted images, followed by postgadolinium T1-
weighted images. Microadenomas were defined by a largest
tumour size <10 mm, and macroadenoma,  10 mm. MRI was
performed before surgery, 3 months postsurgery and regularly
during follow-up.
Surgery and remission criteria
All patients underwent sublabial or nasal transsphenoidal micro-
surgery, with the exception of two who were operated on by the
transfrontal route. Four patients had a second surgery: one
scheduled, one for air in the sella and two because of a GH-
secreting residue. Endoscopic transsphenoidal surgery was per-
formed in 24 patients. For all patients, the two neurosurgeons
specified whether macroscopic tumour resection was complete,
incomplete or uncertainly complete. Any surgical complication
was noted, as were the anatomopathological and immunohisto-
chemical characteristics of each tumour.
Patients were considered to be in short-term remission when
they had normal IGF-1 levels for their age and gender and a GH
nadir <04 lg/l after an OGTT 3 months postsurgery. For dia-
betic patients (unreliable GH values after an OGTT, n = 9), only
IGF-1 measurement was taken into account. Patients who
received a medical treatment at the time of surgery or who did
not stop this treatment at least 3 months before surgery had
their IGF-1 immediately postsurgery excluded from analysis
(n = 53). Values of mean GH and nadir of GH after OGTT
immediately after surgery of patients who received a medical
treatment that was not interrupted at least 2 months before sur-
gery were excluded from analysis (n = 9). Patients who received
adjuvant treatment immediately after surgery (n = 14) were not
considered to be in remission (3-month GH and IGF-1 values
were excluded). Patients with discordant results [normal IGF-1
but GH nadir after OGTT  04 lg/l (n = 17), elevated IGF-1
but GH nadir after OGTT <04 lg/l (n = 10)] were considered
to be in ‘uncertain remission’. Ninety-nine patients who had a
follow-up superior to 6 months were considered for long-term
evaluation. Recurrence was defined as elevated IGF-1 levels or
inadequate GH suppression ( 04 lg/l) after an OGTT during
follow-up. Patients were considered to be in long-term remission
if they had normal IGF-1 levels with no medication at last visit
(only patients in remission after surgery alone were considered
for statistical evaluation of long-term remission after surgery,
n = 49). If IGF-1 was normalized with ongoing treatment, they
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were considered ‘controlled’, and if IGF-1 was elevated, ‘uncon-
trolled’.
Statistical analyses
Descriptive statistics with quantitative variables were expressed
as mean ± standard deviation (SD) and, for long-term follow-up
in median with ranges (minimum–maximum). Univariate com-
parisons between groups were made by two-tailed Student’s
unpaired t-test or ANOVA for continuous variables (variance
equality was verified by the Le´ve´ne´ test and Welch correction
was applied if necessary). Two-tailed Pearson’s chi-square or
Fisher’s exact test were used for comparison of qualitative data.
Variables with P-value < 025 were selected (following Mickey
and Greenland recommendations13) for the multivariate analysis
as well as interactions between covariates. Forward stepwise
logistic regression analysis was used for multivariate studies,
with selection based on likelihood ratio. The remaining covari-
ates were considered significant if P-value < 005.
The following variables were considered for analysis: clinical
data (age at diagnosis, age at surgery, blood pressure: systolic and
diastolic, body mass index), biological data (GHm, IGF-1, GH
after OGTT at diagnosis), imaging data (size of adenoma, inva-
siveness, characteristics: micro vs macroadenoma at diagnosis),
visual field abnormalities and hormonal data at diagnosis (hyper-
prolactinaemia, pituitary deficits), anatomo-pathological data
(pure GH-secreting adenoma or not), surgery (endoscopic way,
surgeon report of macroscopic resection). Furthermore, biological
data (GHm, IGF-1 and GH nadir after OGTT) immediately post-
surgery were considered for short-term remission and the same
parameters at 3 months postsurgery for long-term remission.
Results
Table 1 shows the general characteristics of the 115 acromegalic
patients at diagnosis. Table 2 shows hormonal and imaging data.
Patients were followed up for a mean period of 456 ±
381 months, median 358 months, range 29–1354 months. Sev-
enty patients (609%) received medical treatment before surgery
(somatostatin analogues or dopamine agonists) for a mean dura-
tion of 91 ± 138 months (1–108). Most of the patients received
somatostatin analogues alone (55 patients, or 786%, who received
Octreotide, n = 30 or Lanreotide, n = 25), a few of them dopa-
mine agonists alone (two patients, 29%, Cabergoline) and some
patients an association of both treatment (13 patients, 185%).
Surgery and early postoperative results
Anatomopathological analysis and immunohistochemistry found
56 pure GH adenomas and 58 mixed adenomas (GH-prolactin,
GH-a-subunit and GH-prolactin-a-subunit), one was not inter-
pretable. Staining for Ki-67/MIB-1 was not available. Severe sur-
gical complications were reported in nine patients (78%) (3
permanent diabetes insipidus, 2 cerebrospinal fluid rhinorrhea, 1
sphenoid sinusitis, 1 repeat surgery for air in the sella, 1 V2
neuralgia, and 1 severe adrenal insufficiency). Transient mild
hyponatraemia was reported in 17 (148%) patients. There was
no postoperative mortality. The evolution of GHm level
(n = 106), standardized IGF-1 (n = 57) and GH nadir after
OGTT (n = 85) just after surgery are summarized in Table 2
and Fig. 1. Fourteen patients who were obviously not in remis-
sion (high GH levels postsurgery, incomplete macroscopic surgi-
cal resection) immediately received an adjunctive treatment,
including somatostatin analogues (n = 11), dopaminergic agon-
ists (n = 2) or pegvisomant (n = 1). One patient was scheduled
to undergo further surgery.
Three-month postoperative results
All patients included had 3-month evaluation (performed
between 29 and 4 months after surgery). Three months postsur-
gery, GHm (n = 88), standardized IGF-1 (n = 97) and GH nadir
after OGTT (n = 88) values are represented in Table 2 and
Fig. 1. Three-month and immediate postsurgery IGF-1 values
differed significantly (Table 2, Fig. 1).
Overall, 43 patients (374%) were in remission at 3 months:
65% of patients with a microadenoma and 316% of patients
with a macroadenoma; 45 patients (391%) were not in remis-
sion. Remission was considered uncertain in 27 patients (235%)
because of discrepant results of IGF-1 and GH nadir after OGTT
(Fig. 2). MRI was performed in 110 patients at 3 months; it was
considered normal for 71 patients (645%). Visual field defects
were also significantly improved by surgery (Table 2).
Table 1. Characteristics at diagnosis of 115 acromegalic patients who
underwent surgery between 1997 and 2007 at Timone Hospital, Marseille
Characteristics at diagnosis (n = 115) Values (range)
Age at diagnosis, years 446 ± 121 (107–69)
Age at surgery, years 455 ± 125 (108–728)
Sex ratio, women/men 12/1
Tumor characteristics, n (%)
Adenoma size, mm 177 ± 99 (3–82)
Microadenoma 20 (174)
Macroadenoma 95 (826)
Invasive 64 (557)
Impact on the visual field* 26 (283)
Pure growth hormone-secreting adenoma 56 (487)
Pituitary function, n (%)
Deficits 51 (443)
One deficit 46 (400)
Two deficits 4 (35)
Three deficits 1 (<1)
Hyperprolactinemia 36 (313)
Macroscopic surgical resection, n (%)
Complete 48 (417)
Incomplete 34 (296)
Uncertain 33 (287)
SD, standard deviation.
Unless otherwise stated, values are mean ± SD (range) or number
of patients (%).
*Assessed in 92 patients.
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Predictive factors of short-term remission and recurrence
Univariate analysis demonstrated a significant relationship
between 3-month postoperative remission and a number of fac-
tors (Table 3). No significant relationship was observed between
3-month postoperative remission and levels of standardized
IGF-1 or GH nadir after OGTT at diagnosis. There was also no
significant relationship between remission and the use of endo-
scopic technique, tumour immunohistochemical findings
(pure GH-secreting or mixed), hyperprolactinaemia or pituitary
deficits at diagnosis.
In multivariate analyses, low GHm at diagnosis [OR = 098
(096–099), P = 0033] remained a significant predictor of 3-
month postsurgical remission, as did tumour invasion [OR = 022
(0065–0722), P = 0013] and surgeon report of incomplete or
uncertain macroscopic tumour removal [OR = 011 (003–048),
P = 0003 and OR = 025 (0064–0979), P = 0047, respectively].
The group of patients with uncertain remission at 3 months
appeared to be a distinct intermediate group. In addition to dis-
cordant values for IGF-1 and GH nadir after OGTT, these
patients presented with intermediary results, between those of
patients in remission and those not in remission for a number
of other clinical and biochemical variables, including age at
diagnosis (441 years), age at surgery (446 years), GHm at diag-
nosis (229 lg/l) and adenoma size (17 mm).
During the course of the study, two patients (2%) experienced
recurrence at 11 and 114 months of follow-up. Among the 23
patients considered to be in uncertain remission who were fol-
lowed for more than 6 months, 10 (435%) had finally a persis-
tent disease, with an average delay of diagnosis of 117 months,
6 had insufficiently suppressed GH after OGTT and four had an
elevated IGF-1 level. For these patients, an adjuvant treatment
was proposed. Among these 10 patients, at the end of follow-up,
2 received no treatment and still had an active disease, 5 had
their disease controlled by medical treatment (3 on somatostatin
analogues, 1 on pegvisomant and 1 on dopamine agonists) and
3 were considered in remission (among them 2 had gamma
knife).
Long-term follow-up
The majority of patients not in remission or presenting a recur-
rence were treated by adjunctive treatment. As first-line treat-
ment, 40 patients received a medical treatment for a mean
duration of 273 ± 265 months (29 of them, somatostatin ana-
logues), 4 had radiotherapy (1 gamma knife and 3 conventional
radiotherapy) and 3 experienced repeated surgery. Twenty-six
patients had a second-line therapy: 17 received medical treat-
ment for a mean duration of 171 ± 146 months (pegvisomant,
6) and 9 radiotherapy (7 gamma knife and 2 conventional).
Eighteen patients needed a third-line therapy: 15 received medi-
cal treatment for a mean duration of 286 ± 24 months
(somatostatin analogues, 7, and pegvisomant, 5) and 3 radio-
therapy (1 gamma knife, 2 conventional). Nine patients had
fourth-line therapy, consisting in seven medical treatments for a
mean duration of 267 ± 146 months (pegvisomant in 4) and 2
radiotherapy (1 gamma knife, 1 conventional). Finally, only two
patients had fifth-line therapy, two medical treatments, for 12
and 61 months, respectively. Characteristics of postsurgical treat-
ments are detailed in Table 4.
At the last follow-up visit (excluding 16 patients who had
only 3-month assessment data), GHm (n = 49), standardized
IGF-1 (n = 98) and GH nadir after OGTT (n = 45) were all sig-
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Fig. 1 Levels of normalized IGF-1 at diagnosis, immediately postsurgery,
3 months postsurgery and at final visit. Data are shown as
mean ± upper standard deviation. *P < 001 vs presurgery value;
**P < 001 vs immediately postsurgery value; †P < 001 vs 3-month
postsurgery value.
Table 2. Hormonal and imaging characteristics of 115 operated acromegalic patients at diagnosis and during follow-up
Characteristics Presurgery, at diagnosis Immediately postsurgery Three months postsurgery Last visit
BMI (kg/m2) 261 ± 39 261 ± 40
GHm (lg/l) 311 ± 362 44 ± 103* 4 ± 99* 11 ± 14‡
IGF-1 (9ULN) 33 ± 15 17 ± 11* 11 ± 08† 08 ± 06‡
GH nadir/OGTT (lg/l) 258 ± 32 26 ± 56* 12 ± 25* 02 ± 03‡
Hyperprolactinaemia (% patients) 313 26* 26*
Pituitary hormone deficit (% patients) 443 470 230*
Visual field defect (% patients) 283 58* 103* 58*
BMI, body mass index; GHm, mean growth hormone; IGF, insulin-like growth factor; OGTT, oral glucose tolerance test; SD, standard deviation,
ULN, upper limit of normal.
Significant difference (P < 005): *comparison between data after and before surgery; †comparison with immediate postsurgery data; ‡comparison
between data at last visit and at three months postsurgery.
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nificantly decreased from their corresponding 3-month values
(Table 2, Fig. 1). A pituitary deficit was reported in only 23
patients, which was a significant improvement: 12 patients pre-
sented with one deficit, 4 with two deficits and 7 had more than
two deficits. The frequency of hyperprolactinaemia was also sig-
nificantly improved by surgery (Table 2).
Long-term remission status was determined after an average
follow-up of 524 ± 368 months in 99 patients who were fol-
lowed for more than 6 months, with a median of 41 months,
range 67–1354 months. Of these, 56 (566%) had long-term
remission (normal laboratory values without treatment at the
last consultation) and 49 (495%) had achieved this after surgery
alone. Among the 56 patients who were in long-term remission,
at 3-month evaluation, 30 were considered in remission, 16 were
in uncertain remission (among them 3 had persistent disease)
and 10 were not considered in remission (Fig. 2). Furthermore,
in these patients, four received radiotherapy during follow-up
[conventional (n = 1) and gamma knife (n = 3)].
At last visit, acromegaly was controlled by medical treatment
in 34/43 patients not cured by surgery. In nine patients, disease
was still uncontrolled. Among them, 6 received at least one
treatment during follow-up (4 were adjusting their treatment, 2
were waiting for a gamma-knife procedure), while 1 wished to
undergo in vitro fertilization, 1 had nearly normalized laboratory
parameters with no clinical symptoms and one patient was lost
to follow-up.
In multivariate analyses, prognostic factors of long-term
remission, at diagnosis, were GHm levels [OR = 0940 (0883–
0999), P = 0048], adenoma size [OR = 0773 (0640–0933),
P = 0007] and absence of pituitary deficit [OR = 0123
(0019–0780), P = 0026]. Three-month postsurgery, GH nadir
after OGTT [OR = 0195 (0060–0634), P = 0007] and IGF-1
[OR = 069 (007–0674), P = 0021] were also found to be
predictive of long-term remission.
Table 3. Significant predictive factors of 3-month remission in
univariate analysis
Predictive factor
3-month
remission
(n = 43)
3-month no
remission
(n = 45)
Significance
(P-value)
Age at diagnosis (years) 484 ± 109 420 ± 134 <005
Age at surgery (years) 490 ± 108 427 ± 131 <005
GHm at diagnosis (lg/l) 207 ± 267 457 ± 447 <001
Adenoma size (mm) 137 ± 56 220 ± 123 <0001
Macro/microadenoma
(% patients)
698 933 <001
Local invasiveness
(% patients)
2796 822 <0001
Surgeon report of
complete macroscopic
resection (% patients)
628 200 <0001
Postoperative GHm (lg/l) 11 ± 15 87 ± 151 <001
Postoperative GH
nadir/OGTT (lg/l)
11 ± 26 61 ± 84 <001
Postoperative
IGF-1(xULN)
07 ± 02 19 ± 11 <0001
GH, growth hormone; GHm, mean GH; IGF-1, insulin-like growth
factor; NS, not significant; OGTT, oral glucose tolerance test; ULN,
upper limit of normal.
115 patients operated for a GH-secreting
pituitary adenoma between 1997 and 2007
At 3 months
evaluation
Remission
43 patients
Uncertain remission
27 patients
No remission
45 patients
2
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Recurrence
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Fig. 2 Short- and long-term evolution of 115 acromegalic patients who underwent surgery in Timone Hospital, Marseille, France. Uncertain
remission = discrepancy between results of GH after OGTT and IGF-1 (normal IGF-1 and elevated suppressed GH, n = 17; elevated IGF-1 and
normally suppressed GH, n = 10). GH, growth hormone; OGTT, oral glucose tolerance test.
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Discussion
In this study, which reflects the evolution of acromegalic
patients operated on nowadays in a reference centre by dedi-
cated neurosurgeons, almost 91% of operated patients followed
for more than 6 months were in control of their disease after a
mean long-term follow-up of 524 months. Among them, 495%
were in remission after only surgery. Note that with the current
remission criteria, only 374% of patients were considered in
3-month remission (65% for microadenomas and 316% for
macroadenomas), but only 2% of patients experienced recurrent
disease.
The results of the current study are comparable to those of
the few long-term studies in the literature, with 566% of
patients in remission at the end of follow-up and 495% after
only surgery. Long-term remission rates of 44% (16 years of fol-
low-up), 52% (134 years of follow-up) and 61% (mean follow-
up of 54 years) were reported in studies after only surgery.14–16
When all patients in remission and those controlled by treat-
ment in the current study are considered, more than 90% had
controlled disease at the end of follow-up, which is comparable
with results obtained in long-term studies of the last decade, in
which results increased from 82% to 94%, with a mean follow-
up of 78–134 years.14,16,17 In this long-term follow-up, note
that, as in many other studies, we considered IGF-1 levels to be
a determinant of remission. The main reason was that during
medical treatment, GH nadir after OGTT and, even basal GH
are not a good reflection of biochemical control.18 Furthermore,
epidemiological studies have demonstrated that acromegalic
patients with postsurgical IGF-1 normalization have a reduced
disease-related morbidity and a life expectancy overlapping that
of the general population.5,12
One of the main aims of this study was to evaluate the efficacy
of surgery for achieving remission in acromegaly using the cur-
rent stringent criteria first defined by a 2005 international consen-
sus group9 and confirmed by updated guidelines.8 Indeed, in our
study, an overall remission rate of 374% was observed at
3 months postsurgery. This rate reflected that our criteria for
remission were more stringent than those used in other studies
and, additionally, that only 174% of patients had a microadeno-
ma, which is known to be associated with better surgical
outcome. When we took adenoma size into account, the remis-
sion rate was comparable to those in the literature: 65% of
patients with microadenoma were in remission at 3 months in
the current study, compared with 68% (GH nadir
after OGTT  2 lg/l),19 67% (GHm < 25 lg/l)15 and 59%
(GHm < 2 lg/l),20 despite less stringent criteria. Our 316%
remission rate for patients presenting macroadenomas was also
comparable to others in the literature: 25% (GHm < 2 lg/l),
26% (normal IGF-1)20 and 27% (random GH < 25 lg/l with
nadir GH after OGTT < 1 lg/l and normal IGF-1).21 But Jane
et al. recently published on a series of 60 acromegalic patients
who had endoscopic transsphenoidal surgery, with an overall rate
of remission of 70%, using the 2010 criteria. This difference could
be explained by the proportion of macroadenomas (767% vs
826% in our study), the proportion of tumour invasion (25%
Knosp grade 3 or 4 vs 557% invasive tumour in our series), a dif-
ferent study design (elevated IGF-1 levels 2 months after surgery
were drawn again 6 months later to consider remission) or the
surgical approach.22 The only other study using current remission
criteria found an overall postsurgery remission rate of 38% on 24
acromegalic patients (83% macroadenomas) operated on by
endoscopic approach.23
Furthermore, the frequency of tumour recurrence is strongly
associated with accuracy of remission criteria; the more stringent
they are, the lower the short-term remission rate should be, but
also the long-term recurrence rate.24 Indeed, during follow-up,
only 20% of our patients considered in 3 months remission
experienced a recurrence. Higher recurrence rates were reported
in studies using less stringent short-term remission criteria:
Table 4. Postsurgical treatment administered to patients not in 3-month remission or with a recurrence
Treatment after surgery
First-line (n = 47) Second-line (n = 26) Third-line (n = 18) Fourth-line (n = 9) Fifth-line (n = 2)
Medical treatment, n 40 17 15 7 2
Duration of treatment,
months (mean ± SD)
273 ± 265 171 ± 146 286 ± 24 267 ± 146 *
Regimen, n
SA 29 5 7 1 1
DA 5 2 1 1 –
Pegvisomant 5 6 5 4 –
SA + DA 1 1 – – –
SA + Pegvisomant – 3 2 1 1
Repeat surgery, n 4 – – – –
Gamma knife radiosurgery, n 1 7 1 1 –
Conventional radiotherapy, n 3 2 2 1 –
SA, somatostatin analog; DA, dopamine agonist; SD, standard deviation.
*Treatment was received for 12 and 61 months, respectively, in the two patients who received fifth-line treatment.
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54% (normal IGF-1 and/or a basal or glucose-suppressed
GH  2 ng/ml),25 or even 19% (GH < 25 ng/ml with glucose-
suppressed GH < 1 lg/l).15
Long-term follow-up studies have shown that changes in bio-
chemical status are most likely to occur within the first postop-
erative year, and if initial GH postglucose and IGF-1 levels are
discordant.26 In our study, discordant biochemical results at
3 months postsurgery further revealed an intermediary class of
patients considered in ‘uncertain remission’ (235%), who were
at greater risk of recurrence, in fact persistence, presenting inter-
mediary results in terms of GH levels, adenoma and patient
characteristics. Among the 23 patients in ‘uncertain remission’
with long-term follow-up, 10 (435%) were diagnosed as having
persistent disease, with a mean delay of 117 months postsur-
gery. This increased risk has been reported in other studies, with
several groups demonstrating that an abnormal pattern of post-
operative GH suppression was associated with recurrence in
some, but not all, patients.15,27,28 The clinical significance of this
initial discrepancy is still unknown, and management of such
patients should be individualized,11 with more intensive assess-
ments and adapted treatment strategies, especially during the
first year of follow-up.
Finally, this study allowed the identification of the current
prognostic factors particularly linked to remission. Short-term
predictive factors of remission included GHm level at diagnosis,
degree of tumour invasion and surgeon observation of total
macroscopic resection; these findings agreed with those of other
studies15,20,27,29–31 and emphasized the importance of having
dedicated neurosurgeons for such interventions. Their macro-
scopic surgical report was a strong predictor for 3-month remis-
sion, but note also that there was no postsurgical mortality and
only 72% of patients experienced severe surgery complications.
Furthermore, pituitary deficiency and hyperprolactinaemia
improved significantly after surgery (443–23%, P < 001 and
313–26%, P < 001, respectively). These are data to take into
account because hypopituitarism affects patients’ quality of life
and can lead to increased mortality.32 Concerning long-term
remission, multivariate analysis showed the predictive factors at
diagnosis were GHm levels and adenoma size, as well as lack of
a pituitary deficit. Interestingly, 3 months postsurgery GH nadir
after OGTT and IGF-1 were both significant predictors of long-
term remission, as we used these particular data for 3-month
remission criteria, as currently recommended.8 Identifying such
predictive factors should allow physicians to better predict the
postsurgery outcome of acromegalic patients and to adapt their
therapeutic strategy.
Overall, this study is an actualized picture of what should be
expected after surgery when acromegalic patients are followed
up in an expert centre with dedicated neurosurgeons. At long-
term, more than 90% of patients should have their disease con-
trolled, and almost 50% after surgery alone. Also note that
recurrence of acromegaly was rare when we implemented the
current criteria of short-term remission and that prognostic
remission factors at diagnosis included mean growth hormone
level and size and invasion characteristics of adenomas. Further-
more, patients with discrepant 3-month remission criteria
seemed to be at higher risk of developing early recurrence,
which we considered as persistent disease and should undergo a
close initial follow-up. Ongoing research should now focus on
developing treatments33,34 to control disease in all patients and
on improving quality of life in patients not achieving surgical
remission.
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